Objective/Purpose: To evaluate spectral domain optical coherence tomography (SD-OCT) features associated with baseline vision and visual outcomes after 7 monthly ranibizumab doses in the prospective, multicenter Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with macular Edema following Retinal Vein Occlusion (SHORE).
Design: Post-hoc analysis of prospective clinical trial dataSubjects/Participants/Controls: 202 participants in the 15-month, phase IV, SHORE study comparing monthly versus PRN (pro re nata, as-needed) ranibizumab after 7 monthly doses in eyes with retinal vein occlusions (RVO) with macular edema.Methods/Intervention/Testing: The baseline SD-OCT images were assessed for 1) central subfield thickness (CST), 2) presence of vitreomacular adhesion, vitreomacular traction, or epiretinal membrane, 3) presence, location, and amount of intraretinal or subretinal fluid (IRF or SRF), 4) presence, location, and amount of hyperreflective foci (HF), 5) disorganization of retinal inner layers (DRIL), and 6) disruption of external limiting membrane (ELM), ellipsoid zone (EZ), and interdigitation zone (IZ). Univariate and multivariable regression analyses were performed to evaluate the association of these features with baseline BCVA and change in BCVA after 7 initial monthly ranibizumab injections.Main Outcome Measure: Association of SD-OCT features with baseline BCVA and change in BCVA after 7 monthly ranibizumab injections.Results: Prior to therapy, worse baseline BCVA was associated with ERM presence (P=0.0045), thicker SRF (P=0.0006), larger size of intraretinal cysts (P=0.0015), as well as higher % of DRIL (P<0.0001), % ELM disruption (P<0.0001), % EZ disruption (P=0.0003), and % IZ disruption (P=0.0018). In multivariate models, only % ELM disruption independently impacted baseline